DE60037139D1 - Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten - Google Patents
Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheitenInfo
- Publication number
- DE60037139D1 DE60037139D1 DE60037139A DE60037139A DE60037139D1 DE 60037139 D1 DE60037139 D1 DE 60037139D1 DE 60037139 A DE60037139 A DE 60037139A DE 60037139 A DE60037139 A DE 60037139A DE 60037139 D1 DE60037139 D1 DE 60037139D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- amyloidosis
- aromatic compounds
- alpha
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17395899P | 1999-12-30 | 1999-12-30 | |
US09/748,748 US20010047032A1 (en) | 1999-12-30 | 2000-12-26 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
PCT/US2000/035715 WO2001049281A2 (en) | 1999-12-30 | 2000-12-28 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60037139D1 true DE60037139D1 (de) | 2007-12-27 |
Family
ID=26869723
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60037139T Expired - Lifetime DE60037139T4 (de) | 1999-12-30 | 2000-12-28 | Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten |
DE60037139A Expired - Lifetime DE60037139D1 (de) | 1999-12-30 | 2000-12-28 | Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60037139T Expired - Lifetime DE60037139T4 (de) | 1999-12-30 | 2000-12-28 | Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten |
Country Status (10)
Country | Link |
---|---|
US (4) | US20010047032A1 (de) |
EP (1) | EP1244435B9 (de) |
JP (2) | JP4370072B2 (de) |
AT (1) | ATE378043T1 (de) |
AU (1) | AU2612101A (de) |
CA (2) | CA2686468C (de) |
DE (2) | DE60037139T4 (de) |
DK (1) | DK1244435T5 (de) |
ES (1) | ES2295078T3 (de) |
WO (1) | WO2001049281A2 (de) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
JP4633897B2 (ja) * | 2000-08-17 | 2011-02-16 | 長瀬産業株式会社 | 神経突起伸長剤 |
US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
WO2002054083A2 (en) * | 2001-01-03 | 2002-07-11 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
DK1372682T3 (da) * | 2001-03-15 | 2012-08-20 | Proteotech Inc | Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser |
PL205635B1 (pl) * | 2001-04-09 | 2010-05-31 | Inst Farmaceutyczny | Nowe pochodne genisteiny i zawierające je środki farmaceutyczne |
AUPR957001A0 (en) * | 2001-12-19 | 2002-01-24 | Novogen Research Pty Ltd | Isoflavone conjugates, derivatives thereof and therapeutic methods involving same |
US20040260076A1 (en) * | 2002-10-11 | 2004-12-23 | Castillo Gerardo M. | Isolation, purification and synthesis of procyanidin B2 and uses thereof |
JP2003252766A (ja) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | シアニジン3−グルコシドを有効成分とする抗肥満及び/又は抗糖尿病剤 |
US6964784B2 (en) * | 2002-03-07 | 2005-11-15 | Optigenex, Inc. | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
US20050220753A1 (en) * | 2002-03-22 | 2005-10-06 | Beijing Jiankai Technology Co., Ltd | Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them |
US20030229136A1 (en) | 2002-04-18 | 2003-12-11 | Nurulain Zaveri | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents |
SI2527315T1 (sl) * | 2002-05-31 | 2014-06-30 | Proteotech Inc., | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
WO2004060791A1 (en) | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
WO2004096240A1 (en) * | 2003-05-02 | 2004-11-11 | Medpalett Pharmaceuticals As | Anthocyanins useful for the treatment of diabetes, cardiovascular disorders and to lower the risk of adverse effects of hormone replacement therapy |
US20060105036A1 (en) | 2003-05-12 | 2006-05-18 | Stephen Peroutka | Threo-dops controlled release formulation |
US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
MXPA05013692A (es) * | 2003-06-23 | 2006-03-13 | Neurochem Int Ltd | Metodos para tratar trastornos por acumulacion de proteina. |
WO2005025561A1 (en) * | 2003-09-04 | 2005-03-24 | Synergia Pharma, Inc. | Compositions and methods for orthostatic intolerance |
CA2540407A1 (en) * | 2003-09-25 | 2005-03-31 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
CA2543404A1 (en) * | 2003-10-24 | 2005-05-06 | Meiji Seika Kaisha, Ltd. | Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
EP1744761A4 (de) | 2004-04-28 | 2010-01-13 | Molecules For Health Inc | Verfahren zur behandlung oder prävention von restenose und anderen proliferativen gefässstörungen |
CN100496470C (zh) * | 2004-07-19 | 2009-06-10 | 中国科学院上海生命科学研究院 | 多酚及其氧化物的应用 |
US8568637B2 (en) | 2004-08-02 | 2013-10-29 | Ramot At Tel-Aviv University Ltd. | Method of forming a fiber made of peptide nanostructures |
WO2006017763A2 (en) * | 2004-08-04 | 2006-02-16 | Aspira Biosystems, Inc. | Capture and removal of biomolecules from body fluids using partial molecular imprints |
US9216161B2 (en) | 2004-08-13 | 2015-12-22 | Healthpartners Research Foundation | Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity |
US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
US20070122509A1 (en) * | 2004-12-02 | 2007-05-31 | Molecular Research Center, Inc. | Antioxidant dietary supplement compositions and methods for maintaining healthy skin |
US9579298B2 (en) | 2004-12-02 | 2017-02-28 | Piotr Chomczynski | Antioxidant dietary supplement compositions and methods for maintaining healthy skin |
KR100673595B1 (ko) | 2005-03-07 | 2007-01-24 | 영남대학교 산학협력단 | 푸스틴을 포함하는 퇴행성 신경질환 예방 또는 치료용 조성물 |
ATE452632T1 (de) * | 2005-04-07 | 2010-01-15 | Astrum Therapeutics Pty Ltd | Verbindungen zur behandlung von amyloidose und verhinderung des tods von beta-zellen bei diabetes mellitus typ 2 |
CN101180319B (zh) * | 2005-05-20 | 2012-06-27 | 新加坡科技研究局 | 醛结合的类黄酮制剂 |
RU2420513C2 (ru) * | 2005-07-21 | 2011-06-10 | Релайанс Лайф Сайенсиз Пвт Лтд | Соединения для лечения заболеваний, опосредованных липазой |
JP2009504682A (ja) * | 2005-08-11 | 2009-02-05 | ザ スクリプス リサーチ インスティテュート | トランスサイレチンアミロイドーシスのゲニステインによる阻害 |
US20100310587A1 (en) * | 2005-08-29 | 2010-12-09 | Academia Sinica | Immunomodulatory compositions |
WO2007043048A2 (en) | 2005-10-11 | 2007-04-19 | Ramot At Tel Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
ES2277567B1 (es) * | 2005-12-30 | 2008-06-01 | Universidad Del Pais Vasco | Compuestos con propiedades neuroprotectoras. |
US9155792B2 (en) * | 2006-02-13 | 2015-10-13 | Trustees Of Boston University | RecA inhibitors with antibiotic activity, compositions and methods of use |
WO2007118226A2 (en) | 2006-04-07 | 2007-10-18 | Sunten Phytotech Co., Ltd. | Anthracenedione compounds |
WO2007132784A1 (ja) * | 2006-05-15 | 2007-11-22 | Niigata University | アントラキノン誘導体を有効成分として含有する抗精神病薬、認知異常の治療薬 |
CN101091706B (zh) * | 2006-06-23 | 2011-05-04 | 和泓生物技术(上海)有限公司 | 多巴胺转运蛋白激动剂及其用途 |
ATE548034T1 (de) * | 2006-06-28 | 2012-03-15 | Chelsea Therapeutics Inc | Pharmazeutische zusammensetzungen mit droxidopa |
US20080033038A1 (en) * | 2006-07-07 | 2008-02-07 | Shytle R D | Compositions of polyphenols and methods of use |
WO2008011538A2 (en) * | 2006-07-19 | 2008-01-24 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
WO2008019292A2 (en) * | 2006-08-04 | 2008-02-14 | Trustees Of Boston University | Compositions and methods for potentiating antibiotic activity |
US8802638B1 (en) * | 2007-01-25 | 2014-08-12 | University Of South Florida | Flavonoid treatment of glycogen synthase kinase-based disease |
US8778986B1 (en) * | 2007-01-25 | 2014-07-15 | University Of South Florida | Treatment of glycogen synthase kinase-based disease |
EP2117306A4 (de) * | 2007-02-14 | 2010-02-10 | Mars Inc | Neurogene verbindungen |
CN101244074A (zh) * | 2007-02-16 | 2008-08-20 | 首都医科大学宣武医院 | 淫羊藿黄酮及其有效成分在制备促进神经细胞增殖和分化作用药物中的用途 |
WO2008109517A1 (en) * | 2007-03-02 | 2008-09-12 | University Of South Florida | Neurodegenerative disease treatment using jak/stat inhibition |
WO2008112562A1 (en) * | 2007-03-09 | 2008-09-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
EP2514417A3 (de) * | 2007-05-07 | 2013-01-30 | Chelsea Therapeutics, Inc. | Droxidopa und pharmazeutische Zusammensetzung davon, zur Behandlung von Stimmungsstörungen, Schlafstörungen oder Aufmerksamkeitsdefizit-Störungen |
US9707274B2 (en) | 2007-06-08 | 2017-07-18 | Healthpartners Research & Education | Methods for preventing and treating post-traumatic stress disorder (PTSD) |
US20110111014A1 (en) * | 2007-06-26 | 2011-05-12 | Parkinson's Institute | Methods and compositions for treatment of neurological disorders |
EP2030615A3 (de) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen |
US8597640B2 (en) * | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
US20090176718A1 (en) * | 2007-10-31 | 2009-07-09 | David Ribnicky | Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome |
GB0821994D0 (en) * | 2008-12-02 | 2009-01-07 | Ge Healthcare Ltd | In viva imaging method |
HUE028729T2 (en) | 2009-03-09 | 2017-01-30 | Ramot At Tel-Aviv Univ Ltd | Compositions for the prevention and treatment of neurodegenerative diseases |
US9072730B2 (en) * | 2009-05-14 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease |
CA2789484C (en) | 2010-03-08 | 2019-10-22 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
CN101780098A (zh) * | 2010-03-13 | 2010-07-21 | 青岛大学 | 迷迭香酸-杨梅黄酮药物配方及其在治疗帕金森病中的应用 |
KR20110111594A (ko) * | 2010-04-05 | 2011-10-12 | 서울대학교산학협력단 | 알파-시뉴클레인 유래 곱슬 아밀로이드 섬유의 제조방법, 이를 이용한 하이드로젤의 제조 방법 및 그 이용 방법 |
KR101723635B1 (ko) * | 2010-09-28 | 2017-04-05 | 서울대학교 산학협력단 | 전도성 바이오-나노 융합 사슬 및 이의 제조방법 |
US9872850B2 (en) | 2010-12-23 | 2018-01-23 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
WO2012118935A1 (en) * | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
CN102690244A (zh) * | 2011-03-22 | 2012-09-26 | 中国科学院上海生命科学研究院 | 调节α-突触核蛋白积聚的物质及其制药用途 |
JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状(姿勢反射異常)の治療剤 |
JP2013053133A (ja) * | 2011-08-10 | 2013-03-21 | Taisho Pharmaceutical Co Ltd | 認知機能障害の予防及び/または治療用組成物 |
JP6126531B2 (ja) * | 2011-10-03 | 2017-05-10 | 国立研究開発法人国立長寿医療研究センター | タウ凝集阻害剤 |
KR101301253B1 (ko) * | 2011-12-09 | 2013-08-28 | 한국원자력연구원 | 방사선을 이용한 크로메논 유도체의 제조방법 |
WO2013142370A1 (en) * | 2012-03-19 | 2013-09-26 | Varghese John | APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF |
CN102743367A (zh) * | 2012-05-31 | 2012-10-24 | 兰州理工大学 | 路路通鞣质单体的用途 |
CN102940712B (zh) * | 2012-12-07 | 2014-03-19 | 辽宁大学 | 枳实在制备抗朊病毒药物中的应用 |
WO2014127191A1 (en) * | 2013-02-15 | 2014-08-21 | The Regents Of The University Of Michigan | Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins |
CU20130027A7 (es) | 2013-02-28 | 2014-10-30 | Ct De Neurociencias De Cuba | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
US10279012B2 (en) | 2013-03-11 | 2019-05-07 | Healthpartners Research & Education | Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin |
EP2962687B1 (de) | 2013-04-02 | 2019-06-05 | The Doshisha | Tau-aggregationshemmer |
BR102013022567B1 (pt) * | 2013-09-03 | 2021-09-21 | Uniao Brasileira De Educacão E Assistência | Uso de 6-hidroxi-2-piridonas e seus derivados na preparação de uma composição farmacêutica que atue pela inibição da enzima uridina fosforilase humana |
US10314911B2 (en) | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
EP3237066B1 (de) * | 2014-12-23 | 2020-10-21 | Sloan-Kettering Institute for Cancer Research | Polymorph von granaticin b |
CN104546825A (zh) * | 2014-12-30 | 2015-04-29 | 上海中医药大学 | 高良姜素的医药用途 |
KR101636733B1 (ko) * | 2015-02-24 | 2016-07-07 | 인제대학교 산학협력단 | 에키노크롬 a를 유효성분으로 함유하는 운동능력 증진용 건강식품 및 이를 이용한 운동능력 증진방법 |
KR101818084B1 (ko) * | 2015-04-14 | 2018-01-15 | 대구가톨릭대학교산학협력단 | 석송강 추출물 또는 이로부터 분리된 화합물을 포함하는 알츠하이머병의 예방 또는 치료용 조성물-ⅱ |
WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
BR112018012343A2 (pt) | 2015-12-17 | 2018-12-04 | Massachusetts Inst Technology | composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos |
KR102441381B1 (ko) * | 2016-07-18 | 2022-09-07 | (주)아모레퍼시픽 | 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물 |
US11969408B2 (en) | 2017-03-08 | 2024-04-30 | Amazentis Sa | Method for improving mitophagy in subjects |
CA3097521C (en) | 2017-05-15 | 2023-10-17 | Axial Biotherapeutics, Inc. | Inhibitors of microbially induced amyloid |
CN107349199A (zh) * | 2017-07-18 | 2017-11-17 | 华北制药集团新药研究开发有限责任公司 | 榴菌素类化合物的医药用途 |
KR102098780B1 (ko) * | 2017-09-27 | 2020-05-26 | 농업회사법인 대제한약 주식회사 | 블랙쵸크베리 추출물을 포함하는 뇌질환 예방 또는 치료용 약학 조성물 |
CN107823295A (zh) * | 2017-11-28 | 2018-03-23 | 江西中医药大学 | 栀子花在制备改善睡眠障碍或改善记忆力减退或通便或提高免疫力药物或保健食品中应用 |
KR20200106988A (ko) * | 2018-04-13 | 2020-09-15 | 주식회사 그랜메드 | 알츠하이머 병의 병원성 인자로서 그래닌의 확인과, 그래닌의 응집 억제와 알츠하이머 병을 치료하기 위한 조성물 및 방법 |
GB2596491B (en) * | 2018-12-18 | 2022-06-29 | Sang Hee Kim | Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
KR102246444B1 (ko) * | 2018-12-18 | 2021-04-29 | 김상희 | 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선 및 치매 예방 또는 치료용 조성물 |
BR112021014774A2 (pt) * | 2019-02-08 | 2021-09-28 | Industrial Técnica Pecuaria, S.A. | Composição antioxidante compreendendo quercetagetina e ácido gálico |
CN110548023A (zh) * | 2019-09-19 | 2019-12-10 | 天津科技大学 | 胭脂虫红酸在制备抑制β-淀粉样蛋白聚集中的用途 |
CN111096972B (zh) * | 2020-02-25 | 2023-07-14 | 成都医学院 | 一种预防和/或治疗阿尔茨海默症的药物组合物 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3729563A (en) * | 1970-12-08 | 1973-04-24 | Ciba Geigy Corp | Method of treating movement disorders |
US3833732A (en) * | 1973-05-24 | 1974-09-03 | Miles Lab | Method of treating inflammation utilizing alkyl esters of gallic acid |
US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
JP2587842B2 (ja) * | 1987-12-09 | 1997-03-05 | 株式会社ニチレイ | 神経疾患治療・予防剤 |
GB2264707A (en) * | 1991-06-18 | 1993-09-08 | Roger Michael Marchbanks | Acridine derivatives for treating alzheimer's disease |
US5958883A (en) * | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
US5464619A (en) * | 1994-06-03 | 1995-11-07 | The Procter & Gamble Company | Beverage compositions containing green tea solids, electrolytes and carbohydrates to provide improved cellular hydration and drinkability |
GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
US5972956A (en) * | 1995-11-02 | 1999-10-26 | Warner-Lambert Company | Inhibition of amyloidosis by 9-acridinones |
IL120269A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease |
EP0937137A4 (de) * | 1996-06-06 | 2002-10-23 | Univ Washington | Perlecan exprimierende transgene tiere und verfahren zur identifikation von verbindungen zur behandlung der amyloidose |
AU4236297A (en) * | 1996-08-26 | 1998-03-19 | University Of Washington | Therapeutic and diagnostic applications of perlecan domain splice variants |
FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
WO1998015179A1 (en) * | 1996-10-08 | 1998-04-16 | University Of Washington | Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments |
US6933280B2 (en) * | 1996-10-08 | 2005-08-23 | Gerardo Castillo | Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
CA2219605C (en) * | 1996-10-31 | 2002-02-05 | Deepa Ashok Khambe | Method of stimulating gastrointestinal motility with ellagic acid |
US5746441A (en) * | 1996-12-02 | 1998-05-05 | Rockwell Heavy Vehicle Suspension Systems, Inc. | Center beam suspension system |
US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
KR100543151B1 (ko) * | 1997-01-16 | 2006-01-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 산화방지제와의 상승적인 상호작용을 통해 폴리시클릭 페놀계화합물의 세포 보호 효과를 증강시키는 조성물 |
ES2285772T3 (es) * | 1997-05-15 | 2007-11-16 | University Of Washington | Composicion y metodos para tratar la enfermedad de alzheimer y otras amiloidosis. |
US6264994B1 (en) * | 1997-05-15 | 2001-07-24 | University Of Washington | Compositions for treating alzheimer's disease and other amyloidoses |
US20030017998A1 (en) * | 1997-05-16 | 2003-01-23 | Snow Alan D. | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases |
US6346280B1 (en) * | 1997-05-15 | 2002-02-12 | University Of Washington | Composition and methods for inhibiting the formation of brain amyloid deposits |
US5869469A (en) * | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
ES2200366T3 (es) * | 1997-08-28 | 2004-03-01 | University Of Washington | Composiciones de sacaridos para el tratamiento de la enfermedad de alzheimer y otras amiloidoisis. |
US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
JP4537577B2 (ja) * | 1998-03-13 | 2010-09-01 | ユニバーシティ・オブ・ワシントン | アルツハイマー病及びプリオン病の治療に関する抗プラーク療法を特定するコンゴ好染性マルタ十字形アミロイドプラークのinvitroにおける形成 |
US5981168A (en) * | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
KR20000019716A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 |
UA75569C2 (en) * | 1998-12-01 | 2006-05-15 | Reddys Lab Ltd Dr | Pharmaceutical composition of thiadiazolidinedione and method for its manufacture |
US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
CA2427661C (en) * | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
-
2000
- 2000-12-26 US US09/748,748 patent/US20010047032A1/en not_active Abandoned
- 2000-12-28 JP JP2001549649A patent/JP4370072B2/ja not_active Expired - Fee Related
- 2000-12-28 DE DE60037139T patent/DE60037139T4/de not_active Expired - Lifetime
- 2000-12-28 ES ES00989636T patent/ES2295078T3/es not_active Expired - Lifetime
- 2000-12-28 AU AU26121/01A patent/AU2612101A/en not_active Abandoned
- 2000-12-28 AT AT00989636T patent/ATE378043T1/de active
- 2000-12-28 EP EP00989636A patent/EP1244435B9/de not_active Expired - Lifetime
- 2000-12-28 DK DK00989636T patent/DK1244435T5/da active
- 2000-12-28 CA CA2686468A patent/CA2686468C/en not_active Expired - Lifetime
- 2000-12-28 WO PCT/US2000/035715 patent/WO2001049281A2/en active IP Right Grant
- 2000-12-28 DE DE60037139A patent/DE60037139D1/de not_active Expired - Lifetime
- 2000-12-28 CA CA2392709A patent/CA2392709C/en not_active Expired - Lifetime
-
2004
- 2004-01-21 US US10/762,444 patent/US20040152760A1/en not_active Abandoned
-
2007
- 2007-02-23 US US11/710,228 patent/US20070191330A1/en not_active Abandoned
-
2008
- 2008-08-12 JP JP2008207956A patent/JP5366473B2/ja not_active Expired - Fee Related
-
2010
- 2010-09-21 US US12/886,735 patent/US20110065657A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5366473B2 (ja) | 2013-12-11 |
CA2392709A1 (en) | 2001-07-12 |
CA2686468C (en) | 2014-01-28 |
JP2003532634A (ja) | 2003-11-05 |
EP1244435B9 (de) | 2009-05-06 |
US20110065657A1 (en) | 2011-03-17 |
CA2686468A1 (en) | 2001-07-12 |
AU2612101A (en) | 2001-07-16 |
US20010047032A1 (en) | 2001-11-29 |
JP2009001589A (ja) | 2009-01-08 |
EP1244435B1 (de) | 2007-11-14 |
DE60037139T2 (de) | 2008-09-18 |
US20040152760A1 (en) | 2004-08-05 |
JP4370072B2 (ja) | 2009-11-25 |
US20070191330A1 (en) | 2007-08-16 |
DE60037139T4 (de) | 2009-11-19 |
WO2001049281A3 (en) | 2002-05-10 |
DK1244435T3 (da) | 2008-03-17 |
CA2392709C (en) | 2010-03-23 |
ES2295078T3 (es) | 2008-04-16 |
DK1244435T5 (da) | 2009-08-31 |
WO2001049281A2 (en) | 2001-07-12 |
EP1244435A2 (de) | 2002-10-02 |
ATE378043T1 (de) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60037139D1 (de) | Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
EA200200183A1 (ru) | Композиция, содержащая трамадол и противосудорожное лекарственное средство | |
BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
BG66083B1 (bg) | Фармацевтични състави, съдържащи антитела и антитела за профилактика и лечение на амилоидогенно заболяване | |
MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
GB0318447D0 (en) | Therapeutic agents | |
ATE339187T1 (de) | Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt | |
TW200635903A (en) | Therapeutic agents | |
TW200504034A (en) | Therapeutic agents | |
TW200502221A (en) | Novel lactams and uses thereof | |
ATE253918T1 (de) | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel | |
ATE453617T1 (de) | Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien | |
ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
TW200509933A (en) | Therapeutic agents | |
BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
DE69500673D1 (de) | Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind | |
ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
EP1808169A3 (de) | Polyhydroxylierte aromatische Verbindungen zur Behandlung von Amyloidose und $g(a)-Synuklein-Fibrillen-Erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |